PDCD1 and non-small cell lung carcinoma: To date, two PD-1 inhibitors (pembrolizumab and nivolumab) and one PD-L1 inhibitor (atezolizumab) have been approved for first- or second-line treatment of NSCLC by the US Food and Drug Administration (6, <x>7 </x>,7).